US009409977B2

(12) **United States Patent**
Puro

(10) **Patent No.: US 9,409,977 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **HUMANIZED, ANTI-N2 ANTIBODIES**

(71) Applicant: **DecImmune Therapeutics, Inc.**, Cambridge, MA (US)

(72) Inventor: **Robyn J. Puro**, Brookline, MA (US)

(73) Assignee: **DecImmune Therapeutics, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/206,368**

(22) Filed: **Mar. 12, 2014**

(65) **Prior Publication Data**

US 2014/0271628 A1 Sep. 18, 2014

Related U.S. Application Data

(60) Provisional application No. 61/777,647, filed on Mar. 12, 2013.

(51) **Int. Cl.**

C07K 16/18	(2006.01)
A61K 39/395	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/18*** (2013.01); ***A61K 39/39583*** (2013.01); *A61K 2039/505* (2013.01); *C07K 2317/24* (2013.01); *C07K 2317/34* (2013.01); *C07K 2317/92* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,859,205	A	1/1999	Adair et al.
5,928,893	A	7/1999	Kang et al.
6,753,314	B1	6/2004	Giot et al.
7,442,783	B2	10/2008	Carroll et al.
7,863,419	B2	1/2011	Taylor et al.
8,324,352	B2	12/2012	Carroll
9,067,983	B2	6/2015	Carroll
2003/0099656	A1	5/2003	Patti et al.
2003/0202975	A1	10/2003	Tedder
2004/0006208	A1	1/2004	Karpusas et al.
2004/0131607	A1	7/2004	Carroll et al.
2004/0214272	A1	10/2004	Larosa et al.
2005/0276811	A1	12/2005	Carroll et al.
2006/0024296	A1	2/2006	Williams et al.
2007/0071675	A1	3/2007	Wu et al.
2007/0135998	A1	6/2007	Van Vlijmen et al.
2007/0280881	A1	12/2007	Braslawsky et al.
2008/0260731	A1	10/2008	Bernett et al.
2008/0262203	A1	10/2008	Clegg et al.
2009/0176966	A1	7/2009	Carroll et al.
2009/0299038	A1	12/2009	Nakamura et al.
2010/0136684	A1	6/2010	Carroll et al.
2010/0272723	A1	10/2010	Bernett et al.
2011/0098448	A1	4/2011	Korth et al.
2012/0082664	A1	4/2012	Bernett et al.
2012/0093835	A1	4/2012	Carroll
2014/0056871	A1	2/2014	Carroll
2014/0271627	A1	9/2014	Puro

FOREIGN PATENT DOCUMENTS

WO	9108756	A1	6/1991
WO	9636360	A1	11/1996
WO	0018437	A1	4/2000
WO	0032825	A2	6/2000
WO	0164835	A2	9/2001
WO	0175067	A2	10/2001
WO	0188088	A2	11/2001
WO	0193982	A1	12/2001
WO	03055982	A2	7/2003
WO	2004002210	A2	1/2004
WO	2005085288	A2	9/2005
WO	2011071883	A1	6/2011

OTHER PUBLICATIONS

Non-Final Office Action from U.S. Appl. No. 14/206,316, dated Mar. 20, 2015.

Restriction Requirement from U.S. Appl. No. 14/206,316, dated Oct. 14, 2014.

Database EMBL [Online], "Mus musculus VH9D5 mRNA for anti-dsRNA (RDV-RNA) antibody, partial cds.", retrieved from EBI accession No. EM STD:AB050071, Database accession No. AB050071, Apr. 2, 2002.

Mus Musculus Myosin Heavy Chain IX (Myh9), mRNA. [online]. [retrieved on Feb. 23, 2015]. GenBank Accession No. NM-022410.

Rudikoff, et al., "Single Amino Acid Substitution Altering Antigen-Binding Specificity," Proc Natl Acad Sci USA 79:1979-1983; Mar. 15, 1982.

Austen, et al., "Self-Reactive Immunoglobulin M from Peritoneal B Cells Mediates Murine Intestinal Ischemia-Reperfusion Injury." Surgical Forum, 1998, vol. 49, pp. 341-342.

Carroll, M.C., "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity." Ann. Rev. Immunol. (1998) 16, 545-568.

Padlan, "Anatomy of the antibody molecule" Molecular Immun. 31 (3) (1994), pp. 169-217.

Hechtman, et al., "Intestinal Ischemia-Reperfusion Injury is Mediated by Natural Antibody derived from Peritoneal Bl-a Cells." FASEB Journal. 1998, vol. 12, p. A34.

Klimka, et al., "Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning" British Journal of Cancer (2000) 83: pp. 252-260.

Williams, et al., "Intestinal Reperfusion Injury is Mediated by IgM and Complement," J appl. Physiol, 86:938-42 (1999).

"Aspergillus nidulans FGSC A4 chromosome I ANcontig1.116, whole genome shotgun sequence," GenBank Accession No. AACD0I000116.1, retrieved on Feb. 23, 2015.

(Continued)

Primary Examiner — Brian J Gangle

Assistant Examiner — Andrea McCollum

(74) *Attorney, Agent, or Firm* — Mahreen Chaudhry Hoda, Esq.; Carolyn S. Elmore, Esq.; Elmore Patent Law Group P.C.

(57) **ABSTRACT**

The present invention encompasses humanized antibodies that specifically bind N2 peptide, methods for the preparation thereof and methods for the use thereof.

20 Claims, 11 Drawing Sheets